These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 20077245)

  • 1. Biosimilar medicines--new challenges for a new class of medicine.
    Fox A
    J Biopharm Stat; 2010 Jan; 20(1):3-9. PubMed ID: 20077245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars and regulatory authorities.
    Minghetti P; Rocco P; Del Vecchio L; Locatelli F
    Nephron Clin Pract; 2011; 117(1):c1-7. PubMed ID: 20689318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
    Jelkmann W
    Am J Hematol; 2010 Oct; 85(10):771-80. PubMed ID: 20706990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical assessment of biosimilar products.
    Chow SC; Liu JP
    J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of biosimilars--pharmacokinetic and pharmacodynamic considerations.
    Wang YM; Chow AT
    J Biopharm Stat; 2010 Jan; 20(1):46-61. PubMed ID: 20077248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-clinical safety studies on biosimilar recombinant human erythropoietin.
    Parnham MJ; Schindler-Horvat J; Kozlović M
    Basic Clin Pharmacol Toxicol; 2007 Feb; 100(2):73-83. PubMed ID: 17244255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars: how similar or dissimilar are they?
    Roger SD
    Nephrology (Carlton); 2006 Aug; 11(4):341-6. PubMed ID: 16889575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European regulatory guidelines for biosimilars.
    Wiecek A; Mikhail A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic facts about biosimilars.
    Nowicki M
    Kidney Blood Press Res; 2007; 30(5):267-72. PubMed ID: 17622764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
    Brodniewicz-Proba T
    Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New preparations comprising recombinant human growth hormone: deliberations on the issue of biosimilars.
    Ranke MB
    Horm Res; 2008; 69(1):22-8. PubMed ID: 18057913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the bioequivalence of biosimilars The Retacrit case.
    Schellekens H
    Drug Discov Today; 2009 May; 14(9-10):495-9. PubMed ID: 19429509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biosimilars: regulatory status for approval].
    Herrero Ambrosio A
    Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars approval process.
    Zuñiga L; Calvo B
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):374-7. PubMed ID: 19925842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic equivalence of complex drugs.
    Schellekens H; Klinger E; Mühlebach S; Brin JF; Storm G; Crommelin DJ
    Regul Toxicol Pharmacol; 2011 Feb; 59(1):176-83. PubMed ID: 20951177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars: pharmacovigilance and risk management.
    Zuñiga L; Calvo B
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars: current status and future directions.
    Roger SD
    Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.